[ad_1]
New York, January 17, 2023 /PRNewswire/ — Disruptive platform biotech at the heart of Secondcell Bio’s biotech enterprise united arab emirates Verified by IPO documents United States. Known as Chromovert® technology that enables the development of clinical-stage non-addictive pain relievers, Chromocell Therapeutics in January 11, 2023.
In addition to being used to discover non-addictive pain relievers, Chromovert® Used in strategic natural flavor research collaborations with The Coca-Cola Company, Kraft Foods and Nestlé, resulting in the discovery of the first natural salt flavor enhancing ingredient, successfully commercialized to reduce sodium in the diet. The use of this technology in applications ranging from natural flavor discovery to blocking pain illustrates the breadth and scope of the multipurpose discovery tool.
Biological science deals with human cells. Cells that accurately mimic human disease are the basis for discovering new medicines. However, of the large number of cells designed to model disease, only a tiny minority are suitable. Detecting and isolating the best cells is difficult.chameleon® Technology facilitates the detection and purification of extremely rare desired cells that were previously out of reach.
chameleon® was invented by Dr. kambiz shekdar laboratory in later life Gunther BlobelMD, PhD, 1999 Nobel Laureate in Physiology or Medicine, and John D. Rockefeller Jr. Professor and Howard Hughes Medical Institute Investigator rockefeller university exist New York City.CEO, Chromocell Therapeutics Christian Copfly, PhD. Shekdar and Blobel co-founded Chromocell Corporation, with Dr. Shekdar serving as Chief Scientific Officer, as rockefeller university.
And Chromovert® Pioneered in the US, Dr Shekdar is moving it to the UAE through his second company, Secondcell Bio. The high cost and inertia of entrenched teams remains a barrier to many broad-based next-generation technologies. More recently, the UAE has focused on developing a non-oil economy. Emirati groups including sovereign wealth fund Mubadala and the Dubai Future Foundation are investing in the country’s non-oil economy, including life sciences and biotechnology. With no legacy biotechnology in the UAE, stakeholders can pick and choose from cutting-edge improvements of their choice to leapfrog the industry.
“In the UAE, there is no legacy pharma and no dinosaurs to push aside,” Dr Shekdar said. “chameleon® is a disruptive platform technology that opens the floodgates to an era of accelerated drug discovery. “
The pharmaceutical industry has a staggering 98% failure rate in discovering and developing new drugs. This points to an urgent need for improvements at all stages of the process.chameleon® has been shown to improve the process. The proven technology is now largely automated and scalable to numerous medical applications and needs.
Drugmaker Average Revenue Estimates $18.6 billion Global revenue per new drug.The high average failure rate in the current drug discovery and development process pushes up the average cost of manufacturing each new drug by more than $1.8 billion. The automated, more reliable and cost-effective nature of the Chromovert-enabled process allows for a paradigm shift: many drug discovery programs can be conducted in parallel to simultaneously generate a large number of drug candidates for commercialization, all with a greater overall likelihood of success Sex compared to conventional endeavors.
Dr Shekdar provides first-hand accounts of the UAE’s growing biotech industry in his monthly column for WestView News, New York City Inventor is a newspaper edited by Science.
About Secondcell Bio & Chromovert® technology
Secondcell Bio is a life science company aiming to realize the full potential of Chromovert® Science and technology for human health.chameleon® Technology automates and improves the creation of laboratory cells that more accurately mimic human disease, allowing the discovery of superior drug candidates with a greater overall likelihood of success during the remainder of the long and expensive process of developing new drugs. The technology has been validated and successfully commercially applied to a variety of highly sought after but previously unattainable goals. Strategic partnerships with The Coca-Cola Company, Kraft Foods and Nestle use Chromovert® Discover rare natural flavor ingredients for reducing salt and sugar in your diet. The technology has also been used to discover and develop a novel clinical-stage non-addictive pain reliever that has been fast-tracked by the FDA and listed on Gov. Chris Christie White House panel on the opioid epidemic. Painkillers are now the subject of Chromocell Therapeutics’ upcoming IPO.chameleon® was invented by Dr. kambiz shekdarstudying for a Ph.D. in the laboratory of his late supervisor and doctoral supervisor, King Faisal & Nobel laureate rockefeller university professor doctor Gunther Blobel, M.D., Ph.D.more than $100 million was invested to perfect the technology, which is now ready for Large-Scale Drug Discovery™ in the UAE.
Scientific publishing for Chromovert® Nature Springer’s technology, visit: https://link.springer.com/article/10.1007/s10529-021-03101-5.
View original content to download multimedia:https://www.prnewswire.com/news-releases/biotech-venture-in-the-uae-validated-by-ipo-in-the-us-301722877.html
SourceSecondcell Bio, LLC
[ad_2]
Source link